Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
Catherine Thiéblemont, Yasmin Karimi, Hervé Ghesquières, et al.
Leukemia (2024) Vol. 38, Iss. 12, pp. 2653-2662
Open Access | Times Cited: 12

Showing 12 citing articles:

Measurable Residual Disease Testing During Treatment with Bispecific Antibodies for Lymphoma
Gaston Jean-Louis, Hua‐Jay J. Cherng
Cancers (2025) Vol. 17, Iss. 7, pp. 1153-1153
Open Access
Entwicklungen in der Rezidivtherapie des diffusen großzelligen B-Zell-Lymphoms
Bastian von Tresckow, Peter Borchmann
Deleted Journal (2025)
Closed Access
The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL
Austin Kordic, Tycel Phillips, J. Weiss
Cancers (2025) Vol. 17, Iss. 7, pp. 1192-1192
Open Access
Targeting myeloid cells for hematological malignancies: the present and future
Zhenpeng Guan, Zhengqi Zhang, Kaiyan Wang, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
Immunotherapy in chronic lymphocytic leukemia: advances and challenges
Pan Gao, Yang Zhang, Jun Ma, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
An evaluation of epcoritamab as a treatment for relapsed or refractory follicular lymphoma
Francesca Bonello, Pio Manlio Mirko Frascione, Danilo Faraci, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas
Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-12
Closed Access
Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategies
Livia Donzelli, Alice Di Rocco, Luigi Petrucci, et al.
Cancer Treatment Reviews (2025) Vol. 134, pp. 102898-102898
Closed Access
Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present
Jacob Naman, Nihar Shah, Benjamin Heyman
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1711-1711
Open Access
Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada
Isabelle Fleury, David Macdonald, Mona Shafey, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 142-142
Open Access
The Improving Outcomes in Relapsed-Refractory Diffuse Large B Cell Lymphoma: The Role of CAR T-Cell Therapy
Vibor Milunović, Dora Dragčević, Martina Bogeljić Patekar, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

(2024)
Closed Access | Times Cited: 2
Safety Landscape of Bispecific Antibody Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
Rodrigo Fonseca, Alex J. Liu, Blake Langlais, et al.
Deleted Journal (2024) Vol. 2, Iss. 1, pp. 100061-100061
Open Access | Times Cited: 1
Page 1

Scroll to top